Freedom Wealth Alliance’s Alzamend Neuro ALZN Stock Holding History

Freedom Wealth Alliance’s Portfolio ALZN Stock Details ALZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11	Closed	-$8.47K	–	79
2022 Q4	$8.47K	Buy	+11	New	+$15.9K	0.01%	304

Other funds holding ALZN

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Freedom Wealth Alliance's ALZN Position: Q1 2023 in Review

Freedom Wealth Alliance sold out of Alzamend Neuro (ALZN) in Q1 2023, closing a stake of 11 shares — an estimated $8.47K sold.

Freedom Wealth Alliance first reported a position in ALZN in Q4 2022 and held it in 1 quarter. The position peaked at $8.47K in Q4 2022. 24 funds tracked by Wall St. Rank hold ALZN as of Q1 2023.

Freedom Wealth Alliance reported no remaining Alzamend Neuro position as of Q1 2023 after selling out during the quarter.
Freedom Wealth Alliance sold 11 Alzamend Neuro shares in Q1 2023, an estimated $8.47K.
Freedom Wealth Alliance first reported a position in Alzamend Neuro in Q4 2022 and held it in 1 quarter.
Freedom Wealth Alliance's Alzamend Neuro position peaked at $8.47K in Q4 2022.
24 funds tracked by Wall St. Rank held Alzamend Neuro as of Q1 2023.

Based on Freedom Wealth Alliance's 13F filing for Q1 2023, filed 25 Apr 2023.